Ranbaxy launches 2 NDDS Urology products in India

RELATED NEWS Ranbaxy Lab can go upto Rs 415-416 Canadian Federal Court grants favorable decision to Ranbaxy Buy Ranbaxy Labs; target of Rs 558: Sharekhan Ranbaxy's health status in Q4FY06 ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 13/02/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories Limited (Ranbaxy) today announced the launch of two differentiated, Novel Drug Delivery System products in the Urology Segment. Niftran 100mg Capsules (Nitrofurantoin modified release) developed using the Company's R&D capabilities & Eligard 22.5mg & 45mg (Leuprolide Depot), in-licensed from QLT Inc,. USA, have been launched in the Indian market.

 

Commenting on the launch, Mr. Sanjeev I. Dani, Senior Vice President and Regional Director, Asia & CIS, Ranbaxy, said "The launch of Niftran and Eligard reinforces our commitment in the NDDS segment and further consolidates our leadership position in this area. Both these drugs  augment our Urology franchise and present our customers with Innovative drugs which offer superior options and convenience." 

 

Niftran, a Novel Drug Delivery System (NDDS) based product, offers better patient compliance due to Twice-a-day dosage regimen compared to the conventional Four times-a-day dosage regimen with the currently available Nitrofurantoin in the market. Niftran is indicated for the use in Urinary Tract Infections (UTI's) and because of its unique mode of action, shows a low resistance pattern and a high sensitivity towards major urinary tract infections pathogens. 

 

Eligard is an in-licensed product from QLT Inc, USA, indicated for the palliative treatment (management of symptoms) of advanced prostate cancer. There is an increase in the number of Prostate cancer cases being diagnosed in India. Eligard is also an NDDS based hormonal therapy available in dosage forms of 22.5mg (3 months depot) & 45mg (6 months depot). The product offers convenience to the patients with dosing every 3 or 6 months.  Prostatic carcinoma is one of the common forms of cancer prevalent among men.

 

Urinary tract infections are very common among women.  Given  the current available treatment options and emerging resistance to various drugs, Nitrofurantoin seems to be an ideal choice. A recent report confirms that about 90% of E. coli causing UTI, is still susceptible to Nitrofurantoin, a relatively safe drug.  

 

Ranbaxy continues to remain the largest NDDS marketing company with 8% market share within the Novel Drug Delivery System (NDDS) segment. NDDS portfolio contribution to total Ranbaxy sales stands at 9% (Moving Quarter November, 2006)

 

Sourced From: Ranbaxy Laboratories Ltd